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Abstract 
The goal of this project is to engineer gene vectors that target a single tissue type, 
especially striated muscles. A random library of adeno-associated virus (AAV) was constructed 
by shuffling the capsid genes of AAV serotypes 1 to 9, and the resulting chimeric genes were 
screened for muscle specificity by direct in vivo panning. Viruses expressed high in muscles 
were collected, and the process was repeated to construct chimeric AAV library. To further 
improve specificity, in vitro biopanning was done on three types of cultured cells that represent 
kidney, liver and muscles. For the desirable features, selection was based on infection rate, 
preferably high in muscle but low in liver. Using AAV2 as a standard, three reconstructed AAV 
were found to be expressed at higher frequencies in myotubes with comparable or lower 
frequencies in hepatocytes. These recombined AAV would be further selected in vivo through 
tail vein injection in mice to identify the virus that was the most specific to muscles. 
 
Introduction 
Gene therapy has been the frontier of modern medicine to treat a wide range of diseases, 
from inherited diseases, like cystic fibrosis and hemophilia, to cancer, tissue regeneration and 
many others (Qiao et al. 2012). The vectors for gene delivery can be divided into two groups: 
non-viral and viral vectors. Non-viral vectors include liposomes, naked DNA, microbubbles, 
nanoparticles and polymers. Some examples of viral vectors are adenoviruses, adeno-associated 
virus (AAV), retroviruses and lentiviruses (Luo et al. 2015). The requirements for long-term 
gene delivery are the efficient entry into the cells, stable vector genomes, lack of vector toxicity, 
and evasion of host immune systems. None of the currently available vectors meet all the 
requirements, but viral vector AAV has been considered a promising candidate. In fact, 5.3% of 
gene-therapy-related clinical trials in the world have utilized AAV vectors mainly for the genetic 
diseases gene therapy (Murlidharan et al. 2014).  
AAV as A Vector  
AAV is non-enveloped, helper-dependent parvovirus that is about 25 nm in diameter. Its 
small size helps the virus to navigate through the blood stream and enter cells efficiently. AAV 
can transfect both dividing and non-dividing cells, so its range of application is wide (Luo et al. 
2015). In comparison to adenovirus or plasmid-based gene delivery AAV has stable DNA 
genome, and gene expression is prolonged after a single delivery (Hammoudi et al. 2015). In fact, 
the longest transgene expression so far belongs to an AAV-mediated human factor IX gene in 
muscles that expressed for 10 years (Luo et al. 2015). Unlike other viral vectors, AAV is not 
known to cause any diseases, and it elicits immune response minimally (Zinn and Vandenberghe 
2014). For all the above reasons, AAV is an attractive tool for gene delivery. Three scientific 
developments have further enabled AAV to transfer genes: the ability to cross-package AAV 
vectors, or to produce pseudotyped viruses (Rabinowitz et al. 2002; Gao et al. 2002), the 
construction of helper plasmid containing only the essence of adenovirus (Ad) that propagates 
AAV (Xiao et al. 1998), the identification of inverted terminal repeat (ITR) as the primary 
element required for productive infection and the generation of vectors (Xiao et al. 1997). These 
discoveries make it possible to produce recombinant AAV (rAAV) that packages therapeutic 
genes with minimal contamination of the wild-type virions (Murlidharan et al. 2014). 
AAV for Muscle Gene Therapy 
Muscular dystrophies are characterized by the progressive degeneration of multiple 
muscle groups. Duchnene muscular dystrophy (DMD) is a recessively inherited disease that 
happens 1 in 3500 male live births (Odinaka and Nwolisa 2014). It has an early on set, usually 
before 3 years of age, and death occurs in the mid to late twenties.  DMD is caused by a mutation 
in the dystrophin gene on the X chromosome, leading to a lack of functional dystrophin in 
muscle fibers. There are no currently available cures, but various therapeutic approaches are 
under study. While pharmaceutical therapy uses chemical or biochemical substances to restore 
dystrophin or to alleviate the syndromes, gene therapy offers a more permanent solution by 
introducing a transgene coding full-length or partial dystrophin complementary DNA in muscles 
(Pichavant et al. 2014).  
Muscular dystrophy gene therapy requires efficient body-wide muscle gene transfer and 
AAV has effective and stable transduction in striated muscles, but one challenge in AAV-
mediated gene delivery is broad tissue tropism (Yang et al. 2011). AAV naturally evolve into 
multiple serotypes that target various cell types. For example, AAV4 targets heart and lung, and 
AAV 9 targets central nervous system and peripheral tissues. However, transduction of non-
target organs is common in systemic gene transfer. Liver is at particular danger, because large 
amount of blood is filtered by the liver every moment, and what is carried in the blood is likely 
to stay at this filtering organ. As a result, liver is among the most commonly infected tissue in the 
body. This not only reduces the efficiency of transduction to specific cell populations, but 
presents potential safety concerns on ectopic gene expression (Luo et al. 2015; Yang et al. 2011). 
Since there are no natural serotypes that targets heart and muscles with high specificity, directed 
evolution is utilized to synthesize suitable AAV vectors.  
The Construction of a Chimeric AAV Library   
Xiao lab has devoted much energy to engineer gene vectors that efficiently target striated 
muscles after systemic delivery. Researcher Lin Yang constructed a random chimeric AAV 
capsid gene library by DNA shuffling which is a method of random fragmentation followed by 
PCR reassembly to introduce or exchange new genetic mutations (Yang et al. 2011).The capsid 
genes of AAV serotypes 1 to 9 were amplified and mixed in equal ratio. After the genes were cut 
by DNase and purified by agarose gel electrophoresis, the fragments were reassembled by DNA 
polymerase. The random capsid genes were incorporated into plasmid backbones containing 
AAV2 Rep gene and inverted terminal repeats. An infectious AAV library was finally produced, 
using the self-packaging technique developed by Müller et al (2003).  
According to Yang L. et al., in vitro panning based on cultured cell lines has been used 
before, but gene therapy requires the AAV vectors to confront more complicated physiological 
environment in bodies, including serum proteins, endothelial barriers, extracellular matrix barrier 
and many others (2011). Thus to better mimic application environment, in vivo bio-panning was 
employed to assess the infection rate. The chimeric AAV was injected into adult mice via tail 
vein. Limb skeletal muscles and liver were collected three days after injection. Capsid genes 
enriched in muscles were received by PCR amplification, and the products were reshuffled and 
selected for a second time in vivo. The chimeric AAV library consists of capsid genes retrieved 
again from muscles (Yang et al. 2009). Based on the work done by Xiao lab, the goal of this 
paper is to select appropriate chimeric capsid genes for muscle gene therapy. Desirable AAV 
vectors are expected to deliver genes to cardiac or skeletal muscles efficiently, with low 
transfection of the liver.  
 
Materials and Methods 
Chimeric Recombinant AAV vectors 
Chimeric capsids genes were incorporated into packaging plasmids. The construction of 
AAV reporter vector plasmids pAAV-CMV-GFP and pAAV-CMV-LacZ has been described in 
Qiao et al (2011). Recombinant AAV vectors were generated by triple-plasmid transfection 
technique (Xiao et al. 1998). 
Vector Genome Copy Number Determination 
 Viral DNA was extracted with DNeasy blood and tissue kit (Qiagen, cat. No. 69506). 
Vector copy number was determined with a 7300 real-time PCR system (Applied Biosystems). 
TaqMan assay for AAV vector was developed as described in Qiao et al. (2012). 
Differentiation of C2C12 
C2C12 cells were thawed in 37oC water bath, and then cultured in growth media that 
contained DMEM, 10% fetal bovine serum and penicillin-streptomycin. When C2C12 cells 
reached 50% confluence, media was changed to differentiation media that consisted of DMEM, 
2% horse serum and penicillin-streptomycin.  
Transduction of 293, Huh7 and C2C12 by AAV vectors 
A hundred microliter of shuffled or AAV2 vectors containing either GFP or Lac-Z 
reporter genes were inoculated onto 293 (human embryonic kidney) and Huh7 (a liver cancer 
cell line). Virus was washed off after twelve hours of infection. C2C12 cells were transduced at 
different time points of two or three or four days after inducement of differentiation. The same 
procedure was used as that for 293 and Huh7, but with vectors containing Lac-Z only, because 
GFP was found to be an inefficient reporter. 
Infection rate analysis 
Forty-eight hours after the addition of AAV, cells that were infected with GFP-carrying 
vectors were photographed. Cells infected with Lac-Z-carrying vectors were collected and 




Figure 1. GFP expression of AAV2 and HH27 in Huh7. Microscopic photographs were taken 48 
hours after viral infection of Huh7. 
Reporter gene, GFP, was used in 293 and Huh7 cells. A few shuffled AAV appeared to 
infect Huh7 slightly less than AAV2, for example HH27, but the expression of GFP was so low 
that it was hard to tell the difference of infection determinately (Figure 1). There was too much 
background light and little infected cells, and the results were not very informative. GFP does 
not seem to be a suitable reporter gene in this case, so it was not used in the transduction of 
C2C12 done after that of 293 and Huh7.  
 Lac-Z, on the other hand, provides much more information. The protein was collected 48 
hours after transduction, and measured quantitatively. The amount of Lac-Z protein was 
calibrated to 10^6 copies of virus. Virus genome concentrations of crude lysates were measured 
by dot blot. A normalized graph was constructed by dividing the amount of Lac-Z measured in 
cells infected with chimeric AAV by that in wtAAV2 (Figure 2).  
 
Figure 2. Lac-Z expression of twelve shuffled AAV in ratio to WT AAV2 in C2C12 and Huh7. 
Lac-Z proteins levels in infected cells were measured, and calibrated to 10^6 copies of virus. 
Virus genome concentrations of crude lysates were measured by dot blot. The values were 
divided by that of AAV2 to obtain the ratios. 
Since only muscle-specific AAV was desired, those vectors that infect C2C12 at a high 
rate, but Huh7 at a low rate were selected. Thus HH45, 53 and 98 are of particular interest. In 
comparison with AAV2, HH45 infects Huh7 at 39% and HH53 at 18% of the efficiency of 
AAV2, while their infections of C2C12 were moderately higher than AAV2, one at 1.65 and the 
other at 1.17. On the other hand, HH98 infected C2C12 almost six times better than AAV2 did 
(5.49), while kept infection of Huh7 at comparable level with AAV2 (1.12). Thus HH45, 53 and 
98 were selected for further investigation.  
 
Discussion 
Through panning in cultured cells, three chimeric AAV capsid genes are selected out 
from a library of twelve. As the real battle ground and the verdict for AAV as a vector is inside 
bodies, in vivo panning will be done to determine transduction efficiency of the three candidates 
selected. HH45, 53 and 98 will be tested directly in mice. The capsid genes would again be used 
to engineer recombinant AAV that carry Lac-Z reporter genes. CB promoter will be used in the 
place of CMV, because the CMV promoter shuts off quickly in liver and therefore is not reliable 
to evaluate liver expression. Viruses will be made and injected into mice through tail-vein for a 
systemic delivery. Two to three weeks after infection, organs will be collected, sliced and stained 
to see the rate of infection of each chimeric AAV capsid genes. If HH45, 53 and 98 are 
expressed highly in muscles and weakly in liver, they will be suitable vectors for the treatment of 
muscular diseases.  
Besides the HH library constructed by virus retrieval from heart and muscles, Xiao lab 
has other capsid libraries with different tissue focus. The same technique can be employed to 
develop vectors specific to other targets. By increasing specificity and de-targeting liver, the 
technique of directed evolution enables a broader and safer application of AAV for gene therapy.  
In addition to vector selection, chimeric AAV capsid genes are also analyzed to trace the 
origins of each segment. The composition of capsid genes can be paired with the results from 
concentrated panning to discover the specific mutations that lead to the change of transduction in 
certain tissues. The combination of the two projects will create a table that matches mutations 
with desired tissue tropism, which will enable individual tailoring of AAV for gene therapy. 
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